p53 Oncoprotein expression and gene mutations in some keratoacanthomas

Archives of Dermatology

Volumn 133, Issue 2, 1997, Pages 189-193

  Perez, Maritza I ^a,d   Robins, Perry ^b   Biria, Shahriar ^b   Roco, John ^b   Siegel, Eric ^c   Pellicer, Angel ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; MALE; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031027914     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.133.2.189     Document Type: Article

References (45)

1. Isobe M, Emanuel BS, Giovoli D, et al. Localization of gene for human p53 tumor antigen to band 17p13. Nature. 1986;320:84-85.
2. Hollstein M, Sidransky O, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
3. Harris CC. The p53 at the crossroads of molecular carcinogenesis and risk assessment. Science. 1993;262:1980-1981.
4. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature. 1991;351:4453-4455.
5. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523-526.
6. Brash D, Rudolph JA, Simon JA, et al. UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A. 1991;88:10124-10128.
7. Piercall WE, Mukhopadhyay T, Goldberg LH, et al. Mutations in the p53 gene in human cutaneous squamous cell carcinomas. Mol Carcinog. 1991;4:445-449.
8. Rady P, Scinicariello F, Wagner RF, et al. p53 mutations in basal cell carcinomas. Cancer Res. 1992;52:3804-3806.
9. Ziegler A, Leffell DJ, Kunala S, et al. Mutations hot spots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci U S A. 1993;90: 4216-4220.
10. Campbell C, Quinn AG, Ro YS, et al. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol. 1993;100:746-748.
11. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994;54:316-321.
12. Tornaletti S, Pfeifer GP. Slow repair of pyrimidine dimers at p53 mutation hot spots in skin cancer. Science. 1994;263:1436-1438.
13. Nakazawa H, English D, Randel PL, et al. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci U S A. 1994;91:360-364.
14. Funk WD, Pak DT, Karas RH, et al. A transcriptionally DNA-binding site for human p53 protein complexes. Mol Cell Biol. 1992;12:2866-2871.
15. Hermeking H, Eick D. Mediation of c-myc-induced apoptosis of p53. Science. 1994;265:2091-2093.
16. El-Deiry WS, Tokinoz T, Velculescu VE, et al. WAF1: a potential mediator of p53 tumor suppressor gene. Cell. 1993;75:817-825.
17. Li Y, Jenkins CW, Nichols MA, et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogens. 1994;9:2261-2268.
18. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncoprotein gene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell. 1992;69:1237-1245.
19. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor gene protein p53 by DNA-damaging agents. Oncogene. 1993; 8:307-318.
20. Beylot-Barry M, Vergier B, DeMascarel A, et al. p53 oncoprotein expression in cutaneous lymphoproliferations. Arch Dermatol. 1995;131:1019-1024.
21. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A. 1992;89:7622-7626.
22. Hueston JT. Keratoacanthoma, keratoses and Bowen's disease. In: Emmett AJJ, O'Rourke MGE, eds. Malignant Skin Tumors. New York, NY: Churchill Livingstone Inc; 1991:163-172.
23. Ghadially R, Ghadially F. Keratoacanthoma. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in General Medicine. 4th ed. New York, NY: McGraw-Hill Book Co; 1993:848-855.
24. Calonje E, Jones EW. Intravascular spread of keratoacanthoma. Am J Dermatopathol. 1994;14:414-417.
25. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol. 1994;130:181-186.
26. Lee YS. The M p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer. 1994;73:2317-2323.
27. Stephenson TJ, Riyds J, Silcocks PB, et al. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol. 1992;127: 566-570.
28. Shi SR, Key ME, Kaltra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem. 1991; 39:471-478.
29. Wright DK, Manosm MM. Samples preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR Protocols. Orlando, Fla: Academic Press Inc; 1990:153-158.
30. Buchman VL, Chumakov PM, Ninkina NN, et al. A variation in the structure of the protein-coding region of the human p53 gene. Gene. 1988;70:245-252.
31. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991;88:5413-5417.
32. Sanger F, Nickelen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA. 1977;74:5463-5467.
33. Preston DS, Stern RS. Nonmelanoma skin cancer of the skin. N Engl J Med. 1992;327:1649-1662.
34. Jordan RCK, Kahn HJ, From L, et al. Immunohistochemical demonstration of actinically damaged elastic fibers in keratoacanthomas: an aid in diagnosis. J Cutan Pathol. 1991;18:81-66.
35. Korenberg R, Pennys NS, Kowalczyk A, et al. Quantification of S-100 protein-positive cell in inflamed and non-inflamed keratoacanthoma and squamous cell carcinoma. J Cutan Pathol. 1988;15:104-108.
36. Smoller BS, Kwan TH, Said JW, et al. Keratoacanthoma and squamous cell carcinoma of the skin: immunohistochemical location of involucrin and keratin proteins. J Am Acad Dermatol. 1986;4:226-234.
37. Ho T, Horn T, Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol. 1991;127:1167-1171.
38. Kannon G, park K. Utility of peanut agglutinin (PNA) in the diagnosis of squamous cell carcinoma and keratoacanthoma. Am J Dermatopathol. 1990;12:31-36.
39. Kingman J, Callen J. Keratoacanthoma: a clinical study. Arch Dermatol. 1984; 120:736-740.
40. Hendricks WM. Sudden appearance of multiple keratoacanthomas three weeks after thermal burns. Cutis. 1991;47:410-412.
41. Shaw JC, Storrs FJ, Everts E. Multiple keratoacanthomas after megavoltage radiation therapy. J Am Acad Dermatol. 1990;23:1009-1011.
42. Washington CV, Mikhail GR. Eruptive keratoacanthoma en plaque in an immunosuppressed patient. J Dermatol Surg Oncol. 1987;3:1357-1360.
43. Bryant J. Basal cell carcinoma associated with keratoacanthoma. J Dermatol Surg Oncol. 1985;1:1230-1231.
44. Sanchez YE, Requena L. Keratoacanthoma within a superficial spreading malignant melanoma in situ. J Cutan Pathol. 1991;18:288-292.
45. Kubo Y, Urano Y, Yashimoto K, et al. p53 gene mutations in human skin cancer and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol. 1994;102:440-444.